Quadrivalent Ann Arbor strain live-attenuated influenza vaccine

Fatal Influenza B Infections: Time to Reexamine Influenza Research Priorities

(2012) J. A. McCullers et al.   JOURNAL OF INFECTIOUS DISEASES

Myocardial Injury and Bacterial Pneumonia Contribute to the Pathogenesis of Fatal Influenza B Virus Infection

(2012) Christopher D. Paddock et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children

(2012) Stan L. Block et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age

(2012) Roger Baxter et al.   VACCINE

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine

(2012) Carrie Reed et al.   VACCINE

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age

(2012) Roger Baxter et al.   VACCINE

The rationale for quadrivalent influenza vaccines

(2012) Christopher S. Ambrose et al.   Human Vaccines & Immunotherapeutics

Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference

(2011) Allyn Bandell et al.   Expert Review of Vaccines

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years

(2011) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008

(2011) Stephanie A. Irving et al.   Influenza and Other Respiratory Viruses

Clinical manifestations and socio-economic impact of influenza among healthy children in the community

(2011) Susanna Esposito et al.   JOURNAL OF INFECTION

A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years

(2011) Patricia Tennis et al.   VACCINE

A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults

(2011) Stan L. Block et al.   VACCINE

The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies

(2011) Christopher S. Ambrose et al.   VACCINE

Effects of Oseltamivir Treatment on Duration of Clinical Illness and Viral Shedding and Household Transmission of Influenza Virus

(2010) Sophia Ng et al.   CLINICAL INFECTIOUS DISEASES

Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials

(2010) Raburn M. Mallory et al.   PLoS One

Clinical Features of Children Infected With Different Strains of Influenza B in Southern Taiwan

(2009) Chia-Yu Chi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children

(2009) Humberto Bracco Neto et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza

(2009) Nicolas Collin et al.   VACCINE

A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children

(2009) Robert F. Breiman et al.   VACCINE

Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older

(2009) Pierre J.T. De Villiers et al.   VACCINE

Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity

(2009) Robert B. Belshe et al.   VACCINE

Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children

(2008) B. D. Forrest et al.   Clinical and Vaccine Immunology

Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age

(2008) T. Nolan et al.   PEDIATRICS

Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age

(2008) Stan L. Block et al.   VACCINE